Happy Life Tech and Zhaoke Ophthalmology Announce Strategic Collaboration to Advance Innovation in Ophthalmic Clinical Research in China
On December 16, Huaxin Life Technology, a subsidiary of Yidu Tech specializing in life sciences solutions, and Zai Lab Ophthalmology, which focuses on the treatment of ophthalmic diseases, announced that they had reached a strategic cooperation intention. The two parties will join hands to explore and promote the innovative development of clinical ophthalmology research in China.
In accordance with the strategic cooperation intent, HC360 Technology and Zai Lab Ophthalmology will jointly promote the training of clinical research talent, helping to enhance the quality of the scientific research ecosystem. Both parties will also collaboratively explore the development of digital platform networks to improve the efficiency of clinical research and drive the transformation toward patient-centric clinical studies. Furthermore, both sides will commit to exploring the application of remote intelligent technologies to enhance the efficiency of clinical trials.
Guided by the “Healthy China 2030” Planning Outline, the National Medical Products Administration (NMPA) has held multiple rounds of seminars with industry stakeholders since early 2020 and revised the Good Clinical Practice (GCP) for Drug Clinical Trials along with guidance on the application of digital technologies in clinical trials. Recently, various regions across China have successively introduced a series of favorable policies to promote the development of the biopharmaceutical industry and the construction of research-oriented wards/hospitals. As the COVID-19 pandemic further accelerates industry transformation, patient-centric digital technologies are being increasingly adopted in clinical research, making intelligent and remote clinical trials an inevitable trend. Furthermore, closer collaborative innovation among industry, academia, and research institutions is accelerating the digital transformation of clinical trials in China, reducing trial costs, facilitating new drug development, improving the ecosystem of clinical research in China, and ultimately benefiting more patients.
Against this backdrop, the strategic cooperation intention between HLTC (Happy Life Technology) and ZK Ophthalmology is met with heightened expectations. Clinical research spanning the entire product lifecycle serves as a key engine for enhancing standardization in ophthalmic diagnosis and treatment, as well as for advancing high-quality evidence-based medicine. Furthermore, clinical scientific research in the field of eye health represents a medical application scenario where artificial intelligence and digital technologies demonstrate both breadth and depth. As pioneers in their respective fields, the collaboration between HLTC and ZK Ophthalmology undoubtedly constitutes a powerful alliance within the life sciences sector. By leveraging their respective advantages and resources to catalyze collaborative innovation, both parties aim to advance the construction of an integrated ecosystem for the diagnosis and treatment of ophthalmic diseases in China, thereby making positive contributions to the promotion of public eye health.
Dr. Li Xiaoyi, Chairman and CEO of Zai Lab Ophthalmologystated, “As part of China’s digital economy, innovative development in the pharmaceutical industry, particularly in the ophthalmology market, is strongly encouraged and supported by favorable policies. As one of China’s leading ophthalmic pharmaceutical companies, Zocchond Ophthalmology is honored to collaborate with Yidu Tech and its subsidiary, Huaxin Life Science Technology (HLS), which specializes in life science solutions, to further enhance and optimize the clinical research environment within the industry. We firmly believe that, leveraging Zocchond Ophthalmology’s and HLS’s exceptional R&D capabilities and extensive ecosystem network resources, this partnership will undoubtedly promote the digital transformation and ecosystem development of ophthalmic clinical research in China, thereby delivering better healthcare solutions to a broad patient population.”
Gong Rujing, Chairman, Chief Executive Officer, and Founder of Yidu Techstated, “The strategic partnership with Zhaokē Ophthalmology marks another milestone in Yidu Tech’s innovative practices within the life sciences sector. ‘Making value-oriented precision medicine accessible to everyone’ is Yidu Tech’s mission. We firmly believe in the value of artificial intelligence technologies for the healthcare industry and will continue to invest in this area to help improve the health and medical care standards of the nation.”
MedicineXu Jiming, Co-founder of VCBeat, Senior Vice President of the Group, and CEO of Happy Life TechnologyHe stated, “Happy Life Technology is committed to providing patients with truly personalized medicine and joining hands with partners across the board to build an integrated healthcare ecosystem that offers end-to-end support for disease diagnosis and treatment. The collaboration between Happy Life Technology and Zhaokē Ophthalmology represents a key step in implementing this strategy. I believe that through this partnership, both parties will co-create and share value in the field of clinical research, continuously driving the development of the healthcare industry to benefit more patients.”
ZK Eye Care (Stock Code: 6622 on the Hong Kong Stock Exchange) was established in 2017 as a leading ophthalmic pharmaceutical company dedicated to the research, development, and commercialization of ophthalmic therapies to address significant unmet medical needs. The company was listed on the Main Board of the Hong Kong Stock Exchange on April 29, 2021. It has built a pipeline of 25 drug candidates, comprising both innovative drugs and generics, covering five major ophthalmic indications affecting the anterior and posterior segments of the eye. Many of its products are manufactured at its state-of-the-art, fully integrated development and production facility located in Nansha, Guangzhou. With an ambitious growth strategy that includes collaborations with domestic and international pharmaceutical companies, ZK Eye Care is committed to becoming a market leader.
Yidu Tech (Stock Code on the Hong Kong Stock Exchange: 2158) was established in 2014 and has focused on the development and application of medical artificial intelligence and big data technologies since its inception. With the vision of “Data Intelligence, Green Healthcare,” the Group is committed to addressing pain points in intelligent applications across three major healthcare scenarios: regulation, scientific research, and clinical diagnosis and treatment. By strengthening data infrastructure, Yidu Tech empowers the industry and promotes the construction of a secure, inclusive, and value-oriented smart healthcare system. In January 2021, Yidu Tech successfully listed on the Main Board of the Hong Kong Stock Exchange. The Company’s business primarily spans three areas: Big Data Platforms and Solutions, Life Sciences Solutions, and Health Management Platforms and Solutions. These offerings support medical research, healthcare management, regional public health and population health management, and innovative drug R&D, helping to accelerate cost reduction and efficiency improvement in healthcare services, with the mission of making precision medicine accessible to everyone.
Happy Life Technologies (HLT) is a subsidiary of Yidu Tech (2158.HK), specializing in life sciences solutions. Leveraging digital enablement, HLT combines in-depth disease understanding with the team’s extensive clinical experience to build a platform network for life sciences solutions. With an innovative and comprehensive digital management process for clinical trials, HLT is committed to providing end-to-end clinical research services and promoting the digital transformation and upgrading of clinical research.